Abstract
This is the time of paradigm shift in the treatment armamentarium of primary membranous nephropathy which is a common cause of nephrotic syndrome in adult population and has been labelled as a cause of idiopathic primary glomerulopathy in about 90% of patients. It is responsible for about 0.7% cases of end stage kidney disease. However, unfortunately, the optimal treatment for idiopathic membranous nephropathy is still controversial. Rituximab, a chimeric monoclonal anti-CD20 antibody has been found a potential treatment option for idiopathic membranous nephropathy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
